GLYX-13
Geplaatst: wo jul 09, 2014 9:22 pmGLYX-13
GLYX-13 is a nootropic partial agonist of the NMDA receptor - specifically at the glycine binding site. It has been shown to enhance memory and learning in both young adult and learning-impaired, aging rat models. GLYX-13, a tetrapeptide (H-Thr-Pro-Pro-Thr-NH2), readily crosses the blood brain barrier, and has been shown to increase Schaffer collateral-CA1 long-term potentiation in vitro. In concert with a learning task it has also been shown to elevate gene expression of hippocampal NR1, a subunit of the NMDA receptor, in 3-month-old rats. Neuroprotective effects have also been demonstrated in Mongolian Gerbils by delaying the death of CA1, CA3, and dentate gyrus pyramidal neurons under glucose and oxygen-deprived conditions.
Additionally, GLYX-13 has demonstrated antinociceptive activity, which is of particular interest, as both competitive and noncompetitive NMDA receptor antagonists are ataxic at analgesic doses, while GLYX-13 and other glycine subunit ligands are able to elicit analgesia at sub-ataxic doses.
Clinical Trials
Preclinical data indicates that GLYX-13 has a therapeutic index of 500 or more, onset within 20 minutes of administration, and produces antidepressant-like effects lasting approximately two weeks following administration. Currently under development by Naurex Inc, the compound recently completed phase II trials as a treatment for those resistant or non-responsive to traditional antidepressants. On March 3, 2014 the FDA granted Fast Track designation to the investigation of GLYX-13 as adjunctive therapy in major depressive disorder.
Dit klinkt echt boeiend, weet iemand hier meer over?
GLYX-13 is a nootropic partial agonist of the NMDA receptor - specifically at the glycine binding site. It has been shown to enhance memory and learning in both young adult and learning-impaired, aging rat models. GLYX-13, a tetrapeptide (H-Thr-Pro-Pro-Thr-NH2), readily crosses the blood brain barrier, and has been shown to increase Schaffer collateral-CA1 long-term potentiation in vitro. In concert with a learning task it has also been shown to elevate gene expression of hippocampal NR1, a subunit of the NMDA receptor, in 3-month-old rats. Neuroprotective effects have also been demonstrated in Mongolian Gerbils by delaying the death of CA1, CA3, and dentate gyrus pyramidal neurons under glucose and oxygen-deprived conditions.
Additionally, GLYX-13 has demonstrated antinociceptive activity, which is of particular interest, as both competitive and noncompetitive NMDA receptor antagonists are ataxic at analgesic doses, while GLYX-13 and other glycine subunit ligands are able to elicit analgesia at sub-ataxic doses.
Clinical Trials
Preclinical data indicates that GLYX-13 has a therapeutic index of 500 or more, onset within 20 minutes of administration, and produces antidepressant-like effects lasting approximately two weeks following administration. Currently under development by Naurex Inc, the compound recently completed phase II trials as a treatment for those resistant or non-responsive to traditional antidepressants. On March 3, 2014 the FDA granted Fast Track designation to the investigation of GLYX-13 as adjunctive therapy in major depressive disorder.
Dit klinkt echt boeiend, weet iemand hier meer over?
Gekke peptiden zijn dan wel een geschikte kandidaat omdat ze relatief weinig creativiteit vereisen bij de synthese.